Sugi Predict

Sugi Predict / Compounds / Ribose (Furanose)

Ribose (Furanose)

Ribose (Furanose)

SCHEMBL4087975

O=c1nncc[nH]1.OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CDA P32320 8/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ PNP P00491 1/20 0.36
▸ HK1 P19367 2/20 0.36
▸ HK2 P52789 2/20 0.36
▸ PAX8 Q06710 1/20 0.36
▸ SLC28A1 O00337 1/20 0.35
▸ SLC28A2 O43868 1/20 0.35
▸ SLC29A1 Q99808 1/20 0.35
▸ SLC28A3 Q9HAS3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL3400606 0.79 CDA (0.48) CDAMAPTALDH1A1SMN1; SMN2LMNA
Ribose (Furanose) SCHEMBL3497718 0.79 CDA (0.48) CDAMAPTALDH1A1SMN1; SMN2LMNA
Ribose (Furanose) SCHEMBL8833 0.74 LMNA (0.49) ALDH1A1SMN1; SMN2LMNAPOLBPNP
Ribose (Furanose) SCHEMBL142622 0.74 LMNA (0.49) ALDH1A1SMN1; SMN2LMNAPOLBPNP
Ribose (Furanose) SCHEMBL2325834 0.74 LMNA (0.49) ALDH1A1SMN1; SMN2LMNAPOLBPNP
Ribose (Furanose) SCHEMBL3341287 0.74 LMNA (0.49) ALDH1A1SMN1; SMN2LMNAPOLBPNP
Ribose (Furanose) SCHEMBL4083935 0.74 LMNA (0.40) CDAMAPTALDH1A1SMN1; SMN2LMNA
Ribose (Furanose) SCHEMBL2114503 0.73 MAPT (0.42) CDAMAPTALDH1A1SMN1; SMN2HK1
Ribose (Furanose) SCHEMBL3331595 0.73 LGALS1 (0.35) CDAMAPTALDH1A1
Ribose (Furanose) SCHEMBL27517506 0.73 LGALS1 (0.35) CDAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491818-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2009-02-17 — — US disclosed
US-7423143-B2 Nucleic acid labeling compounds AFFYMETRIX. INC. (US) 2008-09-09 — — US disclosed
US-7291463-B2 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2007-11-06 — — US disclosed
US-7282327-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-10-16 — — US disclosed
US-7179905-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-02-20 — — US disclosed
US-20050287563-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2005-12-29 — — US disclosed
US-6965020-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2005-11-15 — — US disclosed
EP-1589025-A2 Nucleic acid labeling compounds Affymetrix, Inc. (US) 2005-10-26 — — EP disclosed
US-20050164268-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2005-07-28 — — US disclosed
EP-1124838-B1 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX INC (US) 2005-06-01 — — EP disclosed
US-20040210045-A1 Nucleic acid labeling compounds MCGALL GLENN (US) 2004-10-21 — — US disclosed
US-20040101892-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2004-05-27 — — US disclosed
US-20040002595-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2004-01-01 — — US disclosed
US-20030232979-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2003-12-18 — — US disclosed
US-20030180757-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2003-09-25 — — US disclosed
US-6596856-B2 For probes, comprising a heterocycle condensed with a cyclic group such as ribofuranose derivative; biotin and 5-carboxyfluorescein derivatives AFFYMETRIX, INC. 2003-07-22 — — US disclosed
US-20020165372-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2002-11-07 — — US disclosed
WO-2000006771-A9 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX INC (US) 2002-08-22 — — WO disclosed
US-20010044531-A1 Nucleic acid labeling compounds AFFYMETRIX, INC. 2001-11-22 — — US disclosed
US-20010018514-A1 NUCLEIC ACID LABELING COMPOUNDS AFFYMETRIX, INC. 2001-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002595-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20030180757-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20050164268-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20040101892-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20010044531-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20050287563-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20010018514-A1 NUCLEIC ACID LABELING COMPOUNDS RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20020165372-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20030232979-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885
US-20040210045-A1 Nucleic acid labeling compounds RNGTT, DUT, FBL CDA 278/4885MAPT 3297/4885ALDH1A1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.